Steven Robinette

Private Equity Investor chez Atlas Venture Advisors, Inc.

Profil

Dr. John Maraganore was founding CEO of Alnylam Pharmaceuticals, where he led the advancement of RNAi therapeutics as a whole new class of medicines, bringing four approved medicines to patients around the world.
Previously John was an officer and management team member for Millennium Pharmaceuticals, Inc. Before that he was director of Molecular Biology and director of Market and Business Development at Biogen, Inc. where he also invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection.
Earlier, he was a scientist at ZymoGenetics, Inc., and the Upjohn Company.
John serves on the boards of BIO and the Termeer Foundation, and on the advisory boards of N-Lorem and Ariadne Labs.
John received his B.S., M.S., and Ph.D.
degrees in biochemistry and molecular biology at the University of Chicago.

Postes actifs de Steven Robinette

Sociétés	Poste	Début
Atlas Venture Advisors, Inc.	Private Equity Investor	01/09/2015

Anciens postes connus de Steven Robinette

Sociétés	Poste	Fin
VIGIL NEUROSCIENCE, INC.	Private Equity Investor	-
Korro Bio, Inc.	Private Equity Investor	-
Disarm Therapeutics, Inc.	Private Equity Investor	-
Disc Medicine Opco, Inc.	Private Equity Investor	-
KYMERA THERAPEUTICS, INC.	Private Equity Investor	-

Formation de Steven Robinette

Imperial College London	Doctorate Degree
University of Florida	Undergraduate Degree